Syndax Pharmaceuticals, Inc. (SNDX) financial statements (2020 and earlier)

Company profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6081130105
Cash and cash equivalents25343524
Short-term investments35479581
Restricted cash and investments 000
Receivables0000
Prepaid expense1111
Deposits current assets1112
Other undisclosed current assets0110
Total current assets:6283133109
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment0000
Long-term investments and receivables  3 
Long-term investments  3 
Other noncurrent assets0000
Total noncurrent assets:1141
TOTAL ASSETS:6484137109
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10555
Accounts payable6122
Accrued liabilities1101
Employee-related liabilities3322
Deferred revenue2
Debt0   
Deferred revenue and credits21
Contract with customer, liability2
Other undisclosed current liabilities71094
Total current liabilities:18161610
Noncurrent Liabilities
Long-term debt and lease obligation0   
Operating lease, liability0
Liabilities, other than long-term debt13151715
Deferred revenue and credits1714
Deferred revenue13
Contract with customer, liability15
Other liabilities0000
Total noncurrent liabilities:14151715
Total liabilities:32313325
Stockholders' equity
Stockholders' equity attributable to parent325310484
Common stock0000
Additional paid in capital527492471389
Accumulated other comprehensive income (loss) (0)(0)0
Accumulated deficit(495)(439)(366)(305)
Total stockholders' equity:325310484
TOTAL LIABILITIES AND EQUITY:6484137109

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenue, net21
Gross profit:2221
Operating expenses(59)(77)(64)(45)
Operating loss:(58)(76)(62)(44)
Nonoperating income (expense)121(1)
Other nonoperating income (expense)(0)(0)(0)0
Net loss attributable to parent:(56)(74)(61)(44)
Preferred stock dividends and other adjustments   (3)
Net loss available to common stockholders, diluted:(56)(74)(61)(47)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(56)(74)(61)(44)
Comprehensive loss:(56)(74)(61)(44)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)0
Comprehensive loss, net of tax, attributable to parent:(56)(74)(61)(44)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: